Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds.

导出 OA

翻译打印收藏纠错

作者： Brandon A,Vara ^[1] ; Samuel M,Levi ^[1] ; Abdelghani,Achab ^[1] ; David A,Candito ^[1] ; Xavier,Fradera ^[1] ; Charles A,Lesburg ^[1] ; Shuhei,Kawamura ^[1] ; Brian M,Lacey ^[1] ; Jongwon,Lim ^[1] ; Joey L,Methot ^[1] ; Zangwei,Xu ^[1] ; Haiyan,Xu ^[1] ; Dustin M,Smith ^[1] ; Jennifer A,Piesvaux ^[1] ; J Richard,Miller ^[1] ; Mark,Bittinger ^[1] ; Sheila H,Ranganath ^[1] ; David J,Bennett ^[1] ; Erin F,DiMauro ^[1] ; Alexander,Pasternak ^[1]

作者单位： Discovery Chemistry, Computational and Structural Chemistry, Quantitative Biosciences, Pharmacokinetics and Drug Metabolism, Oncology Early Discovery, Merck & Co., Inc., Boston, Massachusetts 02115, United States. ^[1]

DOI 10.1021/acsmedchemlett.1c00096

PMID 33859804

发布时间 2024-03-31

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

ACS medicinal chemistry letters

2021年12卷4期

653-661页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds.

ACS medicinal chemistry letters

相似文献

ACS medicinal chemistry letters

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds.

ACS medicinal chemistry letters

相似文献

ACS medicinal chemistry letters

相关期刊

检索历史清除